Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:EOGCVE:STANYSEAMERICAN:SYN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEOGEOG Resources$110.38-2.3%$119.19$102.52▼$138.18$60.88B0.933.24 million shs5.38 million shsSTASanatana ResourcesC$0.11+16.7%C$0.09C$0.08▼C$0.74C$10.69M1.3229,746 shs17,000 shsSYNSynthetic Biologics$0.00$0.97▼$4.56$16.16M1.38197,338 shs57,700 shs10 Stocks Set to Soar in Spring 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEOGEOG Resources-0.97%+1.53%-10.71%-13.24%-17.07%STASanatana Resources0.00%+16.67%+10.53%-8.70%+40.00%SYNSynthetic Biologics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEOGEOG Resources4.5599 of 5 stars4.32.02.50.22.82.51.9STASanatana ResourcesN/AN/AN/AN/AN/AN/AN/AN/ASYNSynthetic BiologicsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEOGEOG Resources 2.53Moderate Buy$141.1127.84% UpsideSTASanatana Resources 0.00N/AN/AN/ASYNSynthetic Biologics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest STA, SENX, EOG, and SYN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/23/2025EOGEOG ResourcesBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$144.00 ➝ $140.004/22/2025EOGEOG ResourcesSusquehannaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetPositive ➝ Positive$161.00 ➝ $156.004/22/2025EOGEOG ResourcesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$135.00 ➝ $133.004/21/2025EOGEOG ResourcesRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingStrong-Buy ➝ Strong-Buy$140.004/21/2025EOGEOG ResourcesKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$150.00 ➝ $140.004/11/2025EOGEOG ResourcesScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeSector Perform ➝ Sector Outperform$150.00 ➝ $130.003/27/2025EOGEOG ResourcesMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$142.00 ➝ $136.003/25/2025EOGEOG ResourcesMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Neutral$148.00 ➝ $140.003/18/2025EOGEOG ResourcesBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$146.00 ➝ $144.003/17/2025EOGEOG ResourcesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$134.00 ➝ $125.00(Data available from 4/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEOGEOG Resources$23.38B2.60$14.39 per share7.67$48.17 per share2.29STASanatana ResourcesN/AN/AC$0.02 per share4.71C$0.01 per shareN/ASYNSynthetic BiologicsN/AN/AN/AN/A$4.95 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEOGEOG Resources$7.59B$11.238.899.563.5829.18%23.77%15.24%5/1/2025 (Estimated)STASanatana Resources-C$2.27M-C$0.01N/A∞N/AN/A-58.40%-54.68%N/ASYNSynthetic Biologics-$14.27M-$1.21N/AN/AN/AN/A-26.14%-22.74%N/ALatest STA, SENX, EOG, and SYN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/1/2025Q1 2025EOGEOG Resources$2.75N/AN/AN/A$5.92 billionN/A2/28/2025Q4 2024EOGEOG Resources$2.55$2.74+$0.19$2.23$5.96 billion$5.59 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEOGEOG Resources$3.903.53%+23.07%34.73%N/ASTASanatana ResourcesN/AN/AN/AN/AN/ASYNSynthetic BiologicsN/AN/AN/AN/AN/ALatest STA, SENX, EOG, and SYN DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date2/27/2025EOGEOG Resourcesquarterly$0.97503.1%4/16/20254/16/20254/30/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEOGEOG Resources0.132.312.07STASanatana Resources3.475.532.01SYNSynthetic BiologicsN/A4.144.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEOGEOG Resources89.91%STASanatana ResourcesN/ASYNSynthetic Biologics74.38%Insider OwnershipCompanyInsider OwnershipEOGEOG Resources0.13%STASanatana Resources10.34%SYNSynthetic Biologics2.15%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEOGEOG Resources2,850551.54 million560.76 millionOptionableSTASanatana Resources3101.84 millionN/ANot OptionableSYNSynthetic Biologics1615.84 million15.50 millionNot OptionableSTA, SENX, EOG, and SYN HeadlinesRecent News About These CompaniesCytiva and Asimov collaborate on next generation cell line design and process developmentApril 30 at 5:33 AM | pharmiweb.comCytiva and Asimov Collaborate on NextGen Cell Line Design and Process DevelopmentApril 29 at 6:49 PM | genengnews.comSynthetic Design emerges with $20M and next-gen ADC platformApril 26, 2025 | bioworld.comSeries A financing at Grove BiopharmaApril 25, 2025 | bioworld.com$30 million helps Grove go after hard-to-treat cancersApril 24, 2025 | thepharmaletter.comSynthetic Design Lab Emerges with $20M to Advance Next-Generation ADCsApril 24, 2025 | finance.yahoo.comUS to Phase Out Many Synthetic Food Dyes, Kennedy and FDA Head SayApril 24, 2025 | usnews.comGrove Biopharma Closes $30 Million Series A Financing to Advance Bionic Biologics™, a New Therapeutic ModalityApril 24, 2025 | finance.yahoo.comPharma startup out of Portal's lab raises $30M for cancer-fighting biologicsApril 24, 2025 | chicagobusiness.comThe Increasing Value Of The Synthetic Biology Market By 2035April 17, 2025 | pharmiweb.comSynthetic control arms: full impact yet to be realisedApril 16, 2025 | msn.comFuture Opportunities In The Synthetic Biology Market Landscape Until 2035April 16, 2025 | pharmiweb.comNewly approved DMARDs can appear less safe due to ‘channeling’ phenomenonApril 8, 2025 | healio.comBiologics Outperform Conventional Therapy in Still’s DiseaseApril 8, 2025 | medscape.comStudy: Treat Adult-Onset Still's Disease With BiologicsApril 4, 2025 | msn.comWhat’s Next in Synthetic Biology?April 2, 2025 | msn.comGenScript Unveils Prime Editing Boost with the Broad Institute DealMarch 19, 2025 | finance.yahoo.comLotte Biologics partners with Asimov for CDMO collaboration in USMarch 14, 2025 | biz.chosun.comGeorge Church spinout GRObio explores strategic alternatives 6 months after $60M series BMarch 13, 2025 | fiercebiotech.comSeattle Hub for Synthetic Biology lands $10M to support ‘DNA Typewriter’ technologyMarch 7, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesNVIDIA vs Qualcomm: Which Is the Better Buy for Q2?By Sam Quirke | April 3, 2025View NVIDIA vs Qualcomm: Which Is the Better Buy for Q2?Buffett’s Next Oil Bet: Why Occidental Is DifferentBy Jea Yu | April 8, 2025View Buffett’s Next Oil Bet: Why Occidental Is Different2 Under-the-Radar Consumer Staples Stocks With Big DividendsBy Jea Yu | April 15, 2025View 2 Under-the-Radar Consumer Staples Stocks With Big DividendsIAMGOLD Stock Climbs as Turnaround Story Gains TractionBy Jeffrey Neal Johnson | April 11, 2025View IAMGOLD Stock Climbs as Turnaround Story Gains Traction2 Defensive Sectors to Protect Your Portfolio During a RecessionBy Ryan Hasson | April 7, 2025View 2 Defensive Sectors to Protect Your Portfolio During a RecessionSTA, SENX, EOG, and SYN Company DescriptionsEOG Resources NYSE:EOG$110.38 -2.55 (-2.26%) As of 03:59 PM EasternEOG Resources, Inc., together with its subsidiaries, explores for, develops, produces, and markets crude oil, natural gas liquids, and natural gas primarily in producing basins in the United States, the Republic of Trinidad and Tobago and internationally. The company was formerly known as Enron Oil & Gas Company. EOG Resources, Inc. was incorporated in 1985 and is headquartered in Houston, Texas.Sanatana Resources CVE:STAC$0.10 +0.02 (+16.67%) As of 03:59 PM EasternSanatana Resources Inc., an exploration stage company, engages in the acquisition, exploration, and development of mineral properties. It explores for copper and gold. The company entered in an option agreement to acquire 80% interest in the Oweegee Dome project covering an area of approximately 31,077 hectares located in in Golden Triangle in British Columbia; and 100% interest in the Empress Property, as well as asset purchase agreement to acquire the Santoy Property comprising 32 cell mining claims covering an area of approximately 551 hectares located in in Ontario. It also holds interests in the Fortune Project consisting of 100% interest in the Enid property, which comprises 41 mineral claims in the Timmins, Ontario region. The company was formerly known as Sanatana Diamonds Inc. and changed its name to Sanatana Resources Inc. in April 2011. Sanatana Resources Inc. was incorporated in 2004 and is headquartered in Vancouver, Canada.Synthetic Biologics NYSEAMERICAN:SYNSynthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Synthetic Biologics, Inc. is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hims & Hers Stock Soars on Novo Nordisk Collaboration 3 Dividend Kings Outshining the Market in 2025 Tesla's Band-Aid Has Been Ripped Off: Rally Mode Engaged Amazon's Earnings Will Make or Break the Stock's Comeback Why D-Wave's Project With Davidson Is a Game-Changer For Quantum NXP Semiconductors: A Buy-and-Hold Stock in the Buy Zone Joby Aviation Shares Eye Breakout After Transition Flight Win Altria’s Resilient Strategy Keeps It a Top Dividend Play in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
